The T-DM1 trial showed that the treatment increased median overall survival for heavily pretreated HER2-positive breast cancer patients by 22.7 months compared to treatment of physician's choice. The study also found reduced incidence of grade 3 or higher adverse events among those assigned T-DM1.
Studies found that patients with delayed breast cancer surgery and chemotherapy had poorer overall and disease-specific survival rates. A delay of up to 90 days in receiving chemotherapy was associated with no adverse outcomes, but prolonged delays led to increased risks of death from the disease.
A study of over 20,000 women with stage IV breast cancer found improved survival rates, especially among those who received initial breast surgery. The median survival increased from 20 to 26 months, and age, tumor size, hormone receptor status, and year of diagnosis were associated with prolonged survival.
A new study reveals that fluctuating food supplies and competition can alter survival of adult fish and cause populations to fluctuate in abundance. The research found strong interactions between the amount of food and the survival rate as well as the number of fish, with more fish leading to less survival due to competing for limited ...
A study found that socioeconomic factors like race, ethnicity, insurance status, and geographic location affect the likelihood of undergoing surgery for early-stage pancreatic cancer. Patients who underwent resection had improved disease-specific survival compared to those who did not, with regional differences in survival rates observed.
New data from clinical trials at Penn Medicine demonstrate the clinical benefits of proton therapy for patients with advanced lung, pancreatic, and spine cancers. Proton therapy has been shown to reduce toxicities and improve survival rates compared to conventional radiation therapy.
Patients with light-chain (AL) amyloidosis treated with high-dose chemotherapy and autologous stem cell transplantation have the greatest success for long-term survival. Nearly one-third of patients achieved up to 20-year survival after treatment.
A recent study published in JAMA Oncology examined cancer-care outcomes among US hospitals and found significant differences in long-term survival rates among four major categories of hospitals: PPS-exempt, NCI cancer centers, AMC, and other hospitals. The analysis revealed substantial gaps in survival rates, with patients treated at P...
A study of 173,797 female breast cancer patients found that catching cancers when they are small makes a difference to survival, even with modern therapies. Traditional factors such as tumour size and lymph node status have a significant influence on overall mortality independent of age and tumour biology.
A new clinical trial has found that cabozantinib, a second-line therapy, controls the growth of advanced kidney cancer more effectively than everolimus. The results show improved progression-free survival and lower tumor growth rates, indicating potential for prolonged survival.
A large study found that aspirin use after a cancer diagnosis significantly increases overall survival rates for patients with gastrointestinal tumours. The researchers analysed data from nearly 14,000 patients and discovered a strong association between aspirin use and improved survival.
The CheckMate 025 phase III clinical trial shows that nivolumab significantly prolongs survival in patients with advanced kidney cancer, regardless of PD-L1 expression. The study found a median overall survival of 25 months for nivolumab-treated patients compared to 19.6 months for those treated with everolimus.
The EUROCARE 5 study shows significant geographical variations in survival from blood cancers in Europe, with the highest five-year relative survival rate for Hodgkin lymphoma at 81% in Northern European countries. In contrast, chronic myeloid leukemia had a significantly lower survival rate of 53%, particularly in Eastern Europe.
A study of nearly 26,000 patients found that DNR orders were not aligned with their predicted neurological survival rates, particularly for those with the worst prognosis. Patients without DNR orders had a significantly higher rate of favorable neurological survival.
Survival rates for extremely preterm infants have increased significantly over the past 20 years, with improvements in maternal/neonatal care leading to reduced complications and mortality. The study found that survival without major complications increased approximately 2 percent per year for infants at 25 to 28 weeks' gestation.
Research shows low-level oil exposure leads to later heart defects, weaker swimming, and reduced survival in Alaskan fish populations. Subtle changes in heart formation have delayed but important consequences for first-year survival, determining the long-term abundance of wild fish populations.
A study of extremely preterm infants found changes in maternal and infant care practices resulting in improved survival rates. Survival without major health problems increased significantly for infants born at 25-28 weeks.
A study found that delayed administration of epinephrine was associated with a decreased chance of 24-hour survival and survival to hospital discharge among children with cardiac arrest. The researchers analyzed data from the Get With the Guidelines-Resuscitation registry and included U.S. pediatric patients who received at least one d...
Researchers found that generic heart medications, specifically nonselective beta-blockers, significantly improved overall survival among ovarian cancer patients. This is attributed to the ability of these drugs to block stress pathways involved in tumor growth and spread, with further research needed to explore their potential benefits.
A new analysis found that patients taking certain heart medications to manage stress may have a longer survival time than those not taking these drugs. Nonselective beta blockers showed the most significant benefit in extending median survival time, particularly among patients with hypertension.
A study published in Neurosurgery found that complete resection of high-grade brain cancer significantly improves survival rates in children. The study revealed a greater survival benefit for female patients compared to male patients. Gross total resection (GTR) improved the chances of survival free of recurrent or progressive cancer o...
A UC Davis study found that nearly one-third of ovarian cancer patients survived at least 10 years after diagnosis, contradicting the common perception of poor survival rates. The research also identified younger, earlier-stage disease and lower-risk tumor types as factors associated with longer survival.
A new Cancer Research UK study reveals that England's cancer survival rates remain lower than those of countries with similar healthcare systems, despite steady improvements. The study found five-year survival from breast cancer improved more in England than in four leading countries, but overall cancer survival was lowest in England.
The study found that regional node irradiation had a marginal impact on overall survival for patients with stage I, II, or III breast cancer. This was accompanied by improved disease-free and distant-disease-free survival rates, but long-term radiation effects remain unknown.
A new study found that increased radiation dose offers no survival benefit for patients with low-risk prostate cancer. In contrast, men with medium- and high-risk cancers saw improved survival rates with higher doses.
A three-year fishery closure around Robben Island increased African penguin chick survival rates by 18%, a significant improvement for the endangered species. The study highlights the importance of small no-take zones in improving demographic parameters of mobile species like the African penguin.
Researchers found improved median survival of patients with low-grade gliomas increasing from 44 months to 57 months between 1999 and 2010. The study suggests more effective chemotherapies contribute to the increased survival, despite a decrease in radiation therapy use.
A pooled analysis of patients with metastatic colorectal cancer (mCRC) treated with bevacizumab found that those with the lowest body mass index (BMI) had significantly shorter overall survival compared to other BMI categories. Progression-free survival was similar across all subgroups.
The five-year survival rate for Canadians with cystic fibrosis who have received a lung transplant is 67 percent, according to new research published in the Journal of Heart Lung Transplantation. Additionally, half of those who have had transplants live beyond 10 years. The study found that factors such as age at transplant and certain...
A study published in Cancer Epidemiology, Biomarkers & Prevention found that lung cancer patients with comorbidities such as chronic obstructive pulmonary disease, diabetes, or congestive heart failure had a higher risk of death. These patients also experienced poorer survival rates at each stage of the disease.
A recent study found that pre-diagnostic short sleep duration and frequent snoring are associated with significantly poorer cancer-specific survival rates among women with breast cancer. The research suggests that improving sleep patterns may motivate and empower cancer patients to enhance their survival rates.
The study found that nivolumab improved median overall survival by 2.4 months and doubled the one-year survival rate compared to chemotherapy. The immunotherapy drug also reduced the risk of dying from lung cancer by 41%.
Researchers developed a model to assess how dams affect sea-run fish populations, finding that abundance and distribution increased when mainstem dams were removed or passage efficiency improved. The model can predict ecological responses of fish populations and evaluate management actions for fish migrating between fresh and saltwater.
A phase III randomized clinical trial suggests that Stereotactic Ablative Radiotherapy (SABR) is equally effective to surgery in treating operable stage I non-small cell lung cancer patients, with better survival rates and lower toxicity. SABR appears to be a suitable alternative for elderly and comorbidity-prone patients.
A Loyola University Medical Center study found that among 205 cases of mesenchymal chondrosarcoma, more than half survived at least five years and 43 percent survived at least 10 years. Survival rates varied depending on tumor location, with axial tumors showing worse outcomes.
A study of over 1.5 million patients found a passing increase in adjusted mortality rates following Massachusetts health insurance reform, suggesting that simply providing insurance incentives and subsidies may not improve survival for trauma patients. The study's findings resolve within a few years, but highlight the need for more com...
A large cohort study found that long-term use of entecavir (ETV) or tenofovir (TDF) results in excellent 5-year survival for Caucasian patients with chronic hepatitis B (CHB), with a significant proportion of deaths coming from liver-unrelated causes. The development of hepatocellular carcinoma plays a major role in mortality.
A recent EORTC trial found that adjuvant Ipilimumab significantly improves recurrence-free survival in patients with completely resected stage III melanoma at high risk of disease recurrence. However, the treatment was also associated with a high rate of immune-related adverse events.
A study by Dartmouth-Hitchcock's Camilo Fadul and colleagues found no correlation between regulatory T cells (Tregs) and patient survival in glioblastoma. The researchers used a novel epigenetic quantitative analysis methodology to quantify lymphocyte populations, including Tregs, in tumor tissue and peripheral blood.
Researchers compared long-term survival, stroke, reoperation, and bleeding events after bioprosthetic vs mechanical prosthetic mitral valve replacement among 3,433 patients. They found no significant difference in survival at 15 years, but significant differences in risk of reoperation, bleeding, and stroke between the two groups.
Therapeutic anti-cancer vaccines have been associated with a statistically significant increase in patient survival, but rarely have a noticeable effect on tumor growth. The study suggests that overall survival, rather than progression-free survival, should be the gold standard for evaluating cancer vaccine efficacy.
A Yale University study found that higher breast cancer treatment costs are associated with better survival rates. Over a decade, Medicare costs increased from $18,100 to $32,600, while five-year survival improved from 38.5% to 51.9%. The cost increase was largely due to chemotherapy and radiation therapy.
Researchers found that young tropical forests experienced significant declines in manakin survival during dry weather associated with El Niño events. In contrast, mature forests showed stable survival rates regardless of climatic shifts, suggesting a constant abundance of fruit resources.
Patients with multiple myeloma who are diagnosed with MGUS first have better overall survival compared to those without prior knowledge. However, the study also found that patients with low M-protein concentration at MGUS diagnosis have poorer MM survival rates.
Australian researchers identified MCL-1 as a critical regulator of breast development and milk production in the mammary gland. This discovery highlights the importance of MCL-1 for all stages of breast development and lactation.
Researchers at Moffitt Cancer Center have identified a key protein signaling pathway involved in the growth and survival of brain tumor stem cells. The neurotrophin pathway controls nerve growth, survival and specialization, and inhibiting TrkB and TrkC receptors can decrease stem cell survival.
A new TGen study finds targeting stroma surrounding cancer cells can improve treatments and extend patient survival in pancreatic cancer patients. High levels of stroma correlate with poor patient survival, with median survival rates ranging from 9-24 months depending on hyaluronan and collagen levels.
Research by UT Southwestern Medical Center Emergency Medicine physicians found that deeper chest compressions result in decreased survival due to collateral damage, while faster compression rates are crucial for survival. The ideal compression rate is between 100-120 beats per minute.
Researchers have discovered that targeting a cell 'survival' protein could help treat some lymphomas, including those cancers with genetic defects that make them resistant to many existing therapies. Removing MCL-1 causes the death and elimination of lymphoma cells that had become resistant to conventional cancer treatments.
A clinical trial combining stereotactic body radiation therapy with erlotinib improved overall and progression-free survival times for stage 4 lung cancer patients. The treatment combination increased survival rates by more than doubling, from 6-9 months to 20 months.
A new study published in the Journal of the American College of Cardiology found that obese heart failure patients have better survival rates than normal-weight patients. Over a 10-year follow-up period, 38% of obese and 45% of overweight patients died compared to 51% of normal weight patients.
The study found that Herceptin significantly improved 10-year survival from 75 percent to 84 percent when added to chemotherapy. Additionally, the 10-year disease-free survival rate increased from 62 percent to 74 percent with the addition of trastuzumab.
A recent clinical trial found that young adults with acute lymphoblastic leukemia (ALL) who received high-intensity pediatric protocols had better overall survival rates, with 78% achieving overall survival and 66% maintaining event-free survival. This is a significant improvement over previous studies for this age range.
Improvements in cancer survival mean half of all people diagnosed today will survive at least 10 years, compared to a quarter 40 years ago. However, cancers like lung, stomach, and pancreatic cancer remain extremely challenging to treat.
The CONCORD-2 study shows extreme variations in 5-year cancer survival estimates among countries, with some countries achieving high survival rates for certain cancers. Improvements are seen in developed countries and South America, but deficiencies remain in developing countries.
A study found that patients with chronic hepatitis C virus infection and advanced fibrosis or cirrhosis who attain SVR have survival rates comparable to those of the general population. However, patients without SVR experience reduced overall survival.
A phase 2 clinical trial found that adding sargramostim to ipilimumab improved overall survival in patients with metastatic melanoma. The combination treatment also had lower toxicity compared to ipilimumab alone.
Researchers found that eribulin improves overall survival of women with metastatic triple negative breast cancer and HER2 negative breast cancer by nearly five months and two months respectively. Eribulin, originally developed from sea sponges, is a microtubule inhibitor that stops cancer cells from separating into new cells.
The CLEOPATRA study demonstrated a significant survival benefit of 15.7 months with the combination therapy, outperforming previous studies. The long-term safety profile and cardiac safety were also maintained.
Adding cediranib to standard chemotherapy improves tumour shrinkage and adds a modest improvement in progression-free survival for patients with relapsed or metastatic cervical cancer. The study, published in Annals of Oncology, shows greater tumour shrinkage and increased median progression-free survival compared to chemotherapy alone.